Treatment with SR18662 significantly lessens progress and proliferation of CRC cells. SR18662 shows enhanced efficacy in minimizing viability of numerous CRC mobile traces. Circulation cytometry analysis following SR18662 cure demonstrates an increase in cells captured in both S or G2/M phases of the mobile cycle and a big increase in the quantity